Avadel Pharmaceuticals plc will host a conference call and live webcast on May 8, 2024, to provide a corporate update and discuss the financial results for the first quarter of 2024. Investors can access the call through dial-in numbers or the company's website.
Avadel Pharmaceuticals plc organizzerà una teleconferenza e una trasmissione web in diretta l'8 maggio 2024 per fornire un aggiornamento aziendale e discutere i risultati finanziari del primo trimestre del 2024. Gli investitori possono accedere alla chiamata tramite numeri di accesso o attraverso il sito web dell'azienda.
Avadel Pharmaceuticals plc realizará una llamada de conferencia y una transmisión en vivo el 8 de mayo de 2024 para proporcionar una actualización corporativa y discutir los resultados financieros del primer trimestre de 2024. Los inversores pueden acceder a la llamada a través de números de marcación o mediante el sitio web de la compañía.
Avadel Pharmaceuticals plc는 2024년 5월 8일에 회사 업데이트를 제공하고 2024년 첫 분기의 재무 결과를 논의하기 위해 컨퍼런스 콜과 생방송 웹캐스트를 개최할 예정입니다. 투자자는 전화 접속 번호나 회사 웹사이트를 통해 콜에 접속할 수 있습니다.
Avadel Pharmaceuticals plc organisera une conférence téléphonique et une diffusion web en direct le 8 mai 2024 pour fournir une mise à jour de l'entreprise et discuter des résultats financiers du premier trimestre de 2024. Les investisseurs peuvent accéder à l'appel via des numéros de téléphone ou le site web de la société.
Avadel Pharmaceuticals plc wird am 8. Mai 2024 eine Telefonkonferenz und ein Live-Webcast veranstalten, um ein Unternehmensupdate zu geben und die Finanzergebnisse für das erste Quartal 2024 zu diskutieren. Investoren können über Einwahlnummern oder die Unternehmenswebsite auf den Anruf zugreifen.
Positive
None.
Negative
None.
DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024.
To access the conference call, investors are invited to dial +1 (800) 715-9871 (U.S. and Canada) or +1 (646) 307-1963 (International) and use the conference ID 2270373. A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.
About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. For more information, please visit www.avadel.com.
When will Avadel Pharmaceuticals provide a corporate update and report first quarter 2024 financial results?
Avadel Pharmaceuticals will provide a corporate update and report first quarter 2024 financial results on May 8, 2024.
How can investors access the conference call?
Investors can access the conference call by dialing +1 (800) 715-9871 (U.S. and Canada) or +1 (646) 307-1963 (International) and using the conference ID 2270373.
Where can investors access the live webcast?
Investors can access the live webcast by visiting the investor relations section of Avadel Pharmaceuticals' website, www.avadel.com.
Will a replay of the webcast be available?
Yes, a replay of the webcast will be archived on Avadel's website for 90 days following the event.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.